Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olaparib in newly diagnosed mCRPC with HRR mutations
NCT05262608Phase 2Unknown
- Sponsor
- Sun Yat-sen Memorial Hospital
- Start
- Dec 2021
- Primary completion
- Feb 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of olaparib in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Sun Yat-sen Memorial Hospital. Primary endpoints: Objective Radiographic Response up to 60 months, Prostate-Specific Antigen Response up to 60 months and 1 more. Status: unknown.
02
Drugs
olaparib
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT05262608.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05262608.